IDEAYA Biosciences (NASDAQ: IDYA) is a clinical-stage biotechnology company dedicated to pioneering precision medicine in oncology. The company focuses on the discovery and development of innovative targeted therapies for cancer patient populations identified through molecular diagnostics. IDEAYA's pipeline features multiple first-in-class and best-in-class synthetic lethality programs, aiming to exploit genetic vulnerabilities in tumors, as well as immuno-oncology therapies designed to enhance the body's immune response against cancer. Their approach integrates advanced biomarker strategies to identify patients most likely to benefit from their treatments, striving to deliver transformative medicines.
The headquarters serves as the primary center for research and development, clinical operations, corporate strategy, business development, and administrative functions, driving the company's mission in precision oncology.
The facility is situated in the Shoreline Technology Park, a campus known for hosting life science companies. It provides modern laboratory and office spaces designed to support advanced scientific research and collaboration.
The work culture at IDEAYA's headquarters is characterized by a strong emphasis on scientific innovation, collaboration, urgency, and a patient-centric approach. Employees are typically mission-driven, focusing on the development of impactful cancer therapies.
Its location in South San Francisco provides IDEAYA with access to a rich ecosystem of academic institutions, research organizations, skilled talent, and potential partners, fostering innovation and growth in the competitive biotech landscape.
While its primary operations and headquarters are in the US, IDEAYA Biosciences establishes a global presence through its clinical trial activities, which are often conducted across North America, Europe, and Asia-Pacific regions. This international reach is crucial for patient recruitment in various oncology indications. Additionally, collaborations with global pharmaceutical partners like GSK, and engagement with international research institutions, extend its operational footprint and support its drug discovery and development programs worldwide.
7000 Shoreline Court, Suite 350
South San Francisco
California
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, IDEAYA Biosciences' leadership includes:
IDEAYA Biosciences has been backed by several prominent investors over the years, including:
In the past 12-13 months, IDEAYA Biosciences strengthened its leadership with the appointment of Dr. Matthew G. Maurer as Chief Development Officer, Hematology, enhancing its capabilities in this key therapeutic area. No major executive departures have been publicly announced during this period.
Discover the tools IDEAYA Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
IDEAYA Biosciences commonly uses the email format combining the first initial and last name. For example, for an employee named Jane Doe, the email address would likely be jdoe@ideayabio.com. This is a standard format in many biotech and pharmaceutical companies.
[first_initial][last]@ideayabio.com
Format
jdoe@ideayabio.com
Example
95%
Success rate
Ideaya Biosciences, Inc. / Business Wire • May 31, 2024
IDEAYA Biosciences announced positive interim results from its Phase 2 clinical trial evaluating darovasertib in combination with crizotinib for patients with metastatic uveal melanoma. The data, presented at ASCO, demonstrated encouraging confirmed overall response rates and median progression-free survival....more
Ideaya Biosciences, Inc. / GlobeNewswire • May 9, 2024
IDEAYA reported its Q1 2024 financial results, highlighting a strong cash position and progress across its clinical pipeline, including updates on its MAT2A, PARG, and Pol Theta Helicase inhibitor programs. The company reiterated key upcoming milestones for its synthetic lethality pipeline....more
Ideaya Biosciences, Inc. / GlobeNewswire • April 3, 2024
IDEAYA Biosciences and GSK expanded their clinical collaboration to evaluate the combination of IDE397 (MAT2A inhibitor) and niraparib (PARP inhibitor) in a Phase 1/2 study for patients with MTAP-deletion bladder cancer, further broadening their joint efforts in precision oncology....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including IDEAYA Biosciences, are just a search away.